This article describes three emerging, novel cancer immunotherapies: BITE, TIL and cancer vaccines are therapies that recognize specific targets on cancer cells and trigger a specific immune response. So far, not all tumor types can benefit from these approaches the best results have been observed in hematological malignancies, melanoma, and lung cancer. These novel biological products are currently being tested in several cancer centers in Switzerland, and physicians must be familiar with these procedures, as some of their patients might be treated with such therapies in the near future.
Keywords: Immunotherapy; Immunothérapie; Immuntherapie; Immunüberwachung; Krebsimpfstoffe; Tumor-infiltrierende Lymphozyten; anticorps bi-spécifiques engageant les cellules T; bi-specific antibody T-cell engager; bi-spezifischer Antikörper T-Zell-Engager; cancer vaccines; immunosurveillance; lymphocytes infiltrant les tumeurs; tumor-infiltrating lymphocytes; vaccins contre le cancer.